Skip to main content
. Author manuscript; available in PMC: 2014 Apr 20.
Published in final edited form as: Surgery. 2012 Dec;152(6):1238–1247. doi: 10.1016/j.surg.2012.08.031

Fig 6.

Fig 6

Comparison of the effects of vandetanib and cabozantinib drug treatment on the expression of key regulatory proteins involved in MTC cells using Western blot analysis. Both TKIs were evaluated for their effects on similar regulatory proteins studied in Fig 5. Withanolides differ from TKIs in their mechanism of action in that the 2 TKIs tested do not inhibit the Akt/mTOR signaling pathway, but rather downregulate RET activity and the MAP kinase pathway. These differences in action suggest a potential for synergy or combination therapy.